MedCity News
JULY 28, 2022
Attorney General Letitia James accused CVS of a scheme starting in 2017 to prevent New York safety net hospitals from using the company of their choice to obtain federal drug subsidies on prescriptions filled at CVS through the 340B program.
Dominic Tyer
JULY 28, 2022
The immediate threat to patient care from COVID-19 has diminished with the passing of the acute phase of the pandemic, but its impact continues to be stubbornly significant
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JULY 28, 2022
Decentralized clinical trials, drug discovery technologies, and partnering strategies between big pharma and startups were among the topics covered during INVEST PharmaTech, a virtual event hosted this week by MedCity News.
Medgadget
JULY 28, 2022
Researchers at the University of Kentucky created a novel membrane that can enzymatically degrade the SARS-CoV-2 spike protein, rendering the virus inactive. The membrane is intended to act as an insert within face masks, providing extra protection for groups at high risk of SARS-CoV-2 exposure, such as health care staff. The researchers functionalized the membrane with subtilisin enzyme, which can degrade the spike protein in as little as 30 seconds.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
JULY 28, 2022
While pharmaceuticals are a critical piece of the treatment landscape for type 2 diabetes, they have been the exclusive and de-facto first-line treatment for too long. Prescription digital therapeutics can and should be considered as part of type 2 diabetes therapies.
Pharmaceutical Technology
JULY 28, 2022
The Emergency Task Force (ETF) of the European Medicines Agency (EMA) has commenced the review of Veru’s sabizabulin to treat hospitalised Covid-19 patients at increased acute respiratory distress syndrome (ARDS) risk. The review will facilitate the use of the therapy for emergency usage in countries in the European Union (EU). Under this process, the ETF will analyse all available data, including findings from a trial in moderate-to-severe Covid-19 patients admitted to hospital who are at incre
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
JULY 28, 2022
Ulcerative colitis (UC), an inflammatory bowel disease, is characterised by inflammation and ulcers in the large intestine, often causing symptoms that impact a patient’s quality of life, including diarrhoea, abdominal pain and cramping, fatigue, weight loss and pain. While the exact cause of UC remains unknown, it is often associated with immune system malfunction.
MedCity News
JULY 28, 2022
Laboratory testing and clinical trial services giant LabCorp plans to spin off its drug development business as an independent, publicly traded company. It’s the latest in a string of corporate moves for the life sciences sector as companies look to streamline operations in order to focus on particular areas of growth.
Pharmaceutical Technology
JULY 28, 2022
Bristol Myers Squibb (BMS) has reported a 2% rise in revenues to $11.9bn in the second quarter (Q2) of 2022 compared to $11.7bn in Q2 last year. The revenue growth was driven by in-line products, mainly Eliquis and Opdivo, as well as the company’s latest product portfolio comprising Abecma, Opdualag and Reblozyl. New LOE products, especially Revlimid and foreign exchange, impacts partially offset the increase in revenues.
MedCity News
JULY 28, 2022
Michael Howell, chief clinical officer of Google, discussed the ways AI and ML are serving healthcare, as well as some lessons he learned since he started working at Google.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
JULY 28, 2022
Discontinuation or non-adherence to antipsychotic treatment is the most common cause of relapse in patients diagnosed with schizophrenia. As such, patients are typically offered continuous antipsychotic pharmacotherapy to prevent recurring episodes of psychosis. The use of long-acting injectable (LAI) formulations of these antipsychotics can help prevent hospitalisations related to symptom relapse, as these products are administered every fortnight or in one to six-month intervals, versus once o
PharmaVoice
JULY 28, 2022
The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.
pharmaphorum
JULY 28, 2022
Supply chain shortages have dominated headlines for several months, and the pharma industry has been no exception. While navigating changes has long been a challenge for the industry, the last two years’ events have made supply chain management significantly more difficult. The pandemic effectively shut down supply chain paths overnight, and as a result, pharmaceutical manufacturers have faced delays and bottlenecks, which have caused drug shortages in healthcare systems.
Medgadget
JULY 28, 2022
Scientists at the Max Planck Institute for Intelligent Systems in Germany have developed tumor-targeting microrobots using bacteria. The team exploited the tendency of bacteria to naturally gravitate towards areas of low oxygen and low ph, which both tend to occur in the vicinity of a tumor. Once near the tumor, the bacteria aggravate the immune system, with the tumor experiencing some collateral damage.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmaTimes
JULY 28, 2022
The British Heart Foundation’s ‘Big Beat Challenge’ grant of £30m for research into cardiovascular medicine was given to CureHeart
pharmaphorum
JULY 28, 2022
Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks but is already off to a “great start”, according to chief executive Giovanni Caforio. Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS’ PD-1 inhibitor Opdivo (nivolumab) – was approved as a first-line therapy for unresectable or metastatic melanoma by the FDA in March, and garnered $58 million in sales in the second quarter.
PharmExec
JULY 28, 2022
Healthcare advertising agencies can now easily add retail pharmacies to their healthcare media buying strategies.
pharmaphorum
JULY 28, 2022
Dupixent’s march towards becoming one of the world’s top-selling medicines continued at a healthy lick in the second quarter, allowing Sanofi to raise its full-year earnings forecasts. Sales of Dupixent (dupilumab) rocketed 43% to €1.96 billion ($2 billion) – ahead of analyst expectations – driven by buoyant demand in its atopic dermatitis and severe asthma indications fuelled by approvals in earlier age groups.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
JULY 28, 2022
Melinta Therapeutics has signed a licence agreement with Cidara Therapeutics to facilitate a strategic collaboration for marketing the latter’s rezafungin in the US. Rezafungin is a new, once-weekly echinocandin antifungal being developed by Cidara to treat and prevent serious fungal infections such as candidemia and invasive candidiasis in adults. It is also being developed for invasive fungal infection prophylaxis in adults who undergo allogeneic blood and marrow transplantation.
Referral MD
JULY 28, 2022
Photo by Anthony Shkraba on Pexels. At the very onset of the COVID-19 pandemic, healthcare businesses across the US were suddenly faced with new and intense challenges. For the majority, the spread of the pandemic meant an internal disruption. As the uncertainties continue to persist in 2021, the only businesses that will survive and emerge out victorious are the ones that look at new ways to pivot and quickly adapt to their surroundings.
Pharmaceutical Technology
JULY 28, 2022
Here are the largest chemical and pharmaceutical construction projects initiated globally in Q2 2022, according to GlobalData’s construction projects database. 1. Tuas Biomedical Park New Vaccine Production Facility – $467m. The project involves the construction of a new vaccine production facilities at Tuas Biomedical Park in Singapore.
Integrity Solutions
JULY 28, 2022
The term “call centers” is quickly become a relic of the past, and for good reason. Customer service today is based on far from just taking inbound calls; it’s now omnichannel. In addition to answering phone calls, today’s contact center experience typically requires agents to have responsibility for responding to online live web chat, text chat, email requests, website contact form submissions and even social media posts.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Veeva
JULY 28, 2022
With COVID-19 fast-tracking the pharmaceutical industry’s uptake of technology, a slow but sure shift to an omnichannel mindset has become increasingly important for success. For a more personalised HCP experience, it is vital for pharma companies to understand how to engage through the right channels with relevant and compelling content. Earlier this month, Veeva’s APAC commercial team facilitated a discussion with representatives from the Australian pharma industry to share our thoughts on the
PharmExec
JULY 28, 2022
Montague will be responsible for developing and maintaining all relationships, activities and services for his client accounts while leading strategic and tactical planning initiatives for each of them.
Pharmaceutical Technology
JULY 28, 2022
The US Food and Drug Administration's (FDA) recent approval of Roche's Vabysmo (faricimab) for wet age-related macular degeneration (wAMD) in January this year, coupled with anticipated approval of pipeline therapies in the forecast period from 2021 to 2031, as well as potentially first-to-market therapies for geographic atrophy (GA), are all expected to drive the growth of the AMD market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan).
Clarivate
JULY 28, 2022
As a preview to the Clarivate Healthcare Business Insights 2022 Member Retreats coming this fall , we share how health systems are adapting their patient and staff experiences. Having to balance the still increasing demand for consumer-centric processes with a newly volatile job market, hospital and health system leaders have been coming to terms with how staff and patient experiences are often reflective of one another.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
JULY 28, 2022
Osteoarthritis (OA) is a slowly progressive joint disease that is a major cause of disability and pain among the elderly, second only to cardiovascular disease. The OA space is characterised by a high level of unmet clinical need driven by the limited effectiveness of currently available analgesics and the lack of disease-modifying OA drugs (DMOADs).
pharmaphorum
JULY 28, 2022
On the latest instalment of the pharmaphorum podcast, editor in chief Jonah Comstock hosts Dr Benny Alouf, chief medical officer at Limbix to discuss his company’s digital therapeutic for teen depression. Benny discusses SparkRx, Limbix’s product, and how it works, addressing the current regulatory landscape, how digital therapeutics interact with talk therapy and traditional therapeutics, and why it’s important to build a bespoke product for teens.
Pharmaceutical Technology
JULY 28, 2022
Selecting a destination for a greenfield foreign direct investment (FDI) project is a long and sensitive process that no company takes lightly. By carefully weighing up a range of factors, businesses can ensure they are choosing a city or region where their company can access the resources needed to scale multinational operations smartly. In the life sciences sector, one country is significantly outstripping others for FDI.
PharmaTimes
JULY 28, 2022
Patients set to benefit from new treatment for sight-threatening eye condition
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
138 
Let's personalize your content